Chromocell names frank knuettel as chief executive officer, removing interim status held since july 2023

Freehold, n.j., march 18, 2024 (globe newswire) -- chromocell therapeutics corp. (“chromocell”, or the “company”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim ceo frank knuettel, has been appointed as the company's permanent ceo.
CHRO Ratings Summary
CHRO Quant Ranking